De-escalated Neoadjuvant T-DM1 With or Without ET vs Trastuzumab With ET in Hormone Receptor–Positive/HER2-Positive Early Breast Cancer

Janssen Presents First-ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Trial of KN046, a Novel Bispecific Antibody Targeting PD-L1 and CTLA-4 in Patients With Advanced Solid Tumors

HD201 Comparable to Referent Trastuzumab for HER2-Positive Breast Cancer

Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

IMscin001 Part 2: A Randomised Phase 3, Open-label, Multicentre Study Examining the Pharmacokinetics, Efficacy, Immunogenicity, and Safety of Atezolizumab Subcutaneous versus Intravenous in Previously Treated Locally Advanced or Metastatic NSCLC

Menstrual Suppression in the Myelosuppressed: A Retrospective Cohort Study

Camrelizumab Plus Apatinib and Temozolomide as First-line Treatment in Patients With Advanced Acral Melanoma

De-escalated Neoadjuvant T-DM1 With or Without ET vs Trastuzumab With ET in Hormone Receptor–Positive/HER2-Positive Early Breast Cancer

header-info

Mar, 01, 2023

A 5-year follow-up from the phase II WSG-ADAPT-TP trial indicated that pathologic complete response was associated with better outcomes irrespective of receipt of adjuvant chemotherapy among patients with HR+, HER2+ early breast cancer receiving de-escalated neoadjuvant ado-trastuzumab emtansine with or without endocrine therapy vs trastuzumab plus endocrine therapy.